Literature DB >> 15583576

Management of autoimmune bullous diseases: pharmacology and therapeutics.

Diya F Mutasim1.   

Abstract

Bullous diseases are associated with high morbidity and mortality. They result from autoimmune response to one or more components of the basement membrane or desmosomes. Management consists of treating the immunologic basis of the disease, treating the inflammatory process involved in lesion formation, and providing supportive care both locally and systemically. Therapeutic agents are chosen based on their known pharmacologic properties and evidence of effectiveness derived from observations and studies. Learning objectives At the completion of this learning activity, participants should be able to understand the pharmacology of drugs used in the treatment of bullous diseases, the principles of therapy for various such diseases, and a practical approach to the management of these diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583576     DOI: 10.1016/j.jaad.2004.02.013

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  13 in total

Review 1.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 2.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

3.  A practical approach to treating autoimmune bullous disorders with systemic medications.

Authors:  Anne Han
Journal:  J Clin Aesthet Dermatol       Date:  2009-05

Review 4.  The diagnosis and treatment of autoimmune blistering skin diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Dtsch Arztebl Int       Date:  2011-06-10       Impact factor: 5.594

Review 5.  Epidermolysis bullosa and the partnership with autoimmunity: what should we assimilate?

Authors:  Susanna Esposito; Sophie Guez; Francesca Manzoni; Annalisa Bosco; Donato Rigante
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 6.  Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis.

Authors:  Eduardo Liberato da Silva; Taiane Berguemaier de Lima; Pantelis Varvaki Rados; Fernanda Visioli
Journal:  Clin Oral Investig       Date:  2021-08-03       Impact factor: 3.573

7.  Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria.

Authors:  Matt Morgan; Andrew Cooke; Laura Rogers; Beverley Adams-Huet; David A Khan
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Sep-Oct

Review 8.  High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.

Authors:  Norito Ishii; Takashi Hashimoto; Detlef Zillikens; Ralf J Ludwig
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

9.  Therapy of autoimmune bullous diseases.

Authors:  Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

10.  Pulse therapy in pemphigus: report of 11 cases.

Authors:  Nurimar Conceição Fernandes; Mariana Menezes
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.